Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa

Main text

(Molecular Therapy 28, 2139–2149; October 2020)

In the originally published version of this article, it was stated that “The National Institute of Standards and Technology has set the limit for an acceptable CRISPR off-targeting rate in patients at 25%. [56–59]” This percentage is incorrect, so we have elected to redact it entirely from the review.

The authors regret this error.